tbuckley/cabot-search huggingface dataset:
National Latinx AIDS Awareness Day — October 15, 2019
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

National Latinx AIDS Awareness Day, October 15, is observed each year to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on Hispanics/Latinos in the United States. In 2017, 26% of newly diagnosed HIV infections occurred in Hispanics/Latinos (1). Seventy-five percent of these newly diagnosed HIV infections in Hispanics/ Latinos were in men who have sex with men (MSM), and an additional 3% were in MSM who inject drugs (1).
Acta Endocrinologica, Copenhagen
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smile a While
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline <scp>ADMIRE</scp> and <scp>ARCTIC</scp> trials: A comprehensive assessment of prognostic factors
Authors: David John Allsup, Zoe Craig, David Cairns, Dena Howard, Anna Hockaday, Adrian Bloor, Zarni Soe, Christopher Pepper, Valter Gattei, Antonella Zucchetto, Pauline Robbe, Ruth Clifford, Anna Schuh, Talha Munir, Andrew Rawstron, Peter Hillmen
Journal: American Journal of Hematology (2022)

Ten-year follow-up
Current Medical Literature
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis
Authors: Konstantinos Evangelou, Dimitris Veroutis, Koralia Paschalaki, Periklis G. Foukas, Nefeli Lagopati, Marios Dimitriou, Angelos Papaspyropoulos, Bindu Konda, Orsalia Hazapis, Aikaterini Polyzou, Sophia Havaki, Athanassios Kotsinas, Christos Kittas, Athanasios G. Tzioufas, Laurence de Leval, Demetris Vassilakos, Sotirios Tsiodras, Barry R. Stripp, Argyris Papantonis, Giovanni Blandino, Ioannis Karakasiliotis, Peter J. Barnes, Vassilis G. Gorgoulis
Journal: European Respiratory Journal (2022)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the respiratory system can progress to a multisystemic disease with aberrant inflammatory response. Cellular senescence promotes chronic inflammation, named senescence-associated secretory phenotype (SASP). We investigated whether coronavirus disease 2019 (COVID-19) is associated with cellular senescence and SASP.Autopsy lung tissue samples from 11 COVID-19 patients and 43 age-matched non-COVID-19 controls with similar comorbidities were analysed by immunohistochemistry for SARS-CoV-2, markers of senescence and key SASP cytokines. Virally induced senescence was functionally recapitulated in vitro, by infecting epithelial Vero-E6 cells and a three-dimensional alveosphere system of alveolar type 2 (AT2) cells with SARS-CoV-2 strains isolated from COVID-19 patients.SARS-CoV-2 was detected by immunocytochemistry and electron microscopy predominantly in AT2 cells. Infected AT2 cells expressed angiotensin-converting enzyme 2 and exhibited increased senescence (p16INK4A and SenTraGor positivity) and interleukin (IL)-1β and IL-6 expression. In vitro, infection of Vero-E6 cells with SARS-CoV-2 induced senescence (SenTraGor), DNA damage (γ-H2AX) and increased cytokine (IL-1β, IL-6, CXCL8) and apolipoprotein B mRNA-editing (APOBEC) enzyme expression. Next-generation sequencing analysis of progenies obtained from infected/senescent Vero-E6 cells demonstrated APOBEC-mediated SARS-CoV-2 mutations. Dissemination of the SARS-CoV-2-infection and senescence was confirmed in extrapulmonary sites (kidney and liver) of a COVID-19 patient.We demonstrate that in severe COVID-19, AT2 cells infected by SARS-CoV-2 exhibit senescence and a proinflammatory phenotype. In vitro, SARS-CoV-2 infection induces senescence and inflammation. Importantly, infected senescent cells may act as a source of SARS-CoV-2 mutagenesis mediated by APOBEC enzymes. Therefore, SARS-CoV-2-induced senescence may be an important molecular mechanism of severe COVID-19, disease persistence and mutagenesis.
Endoscopy International Open – recently published
Journal: Endoscopy (2022)

Comment on: Endoscopic characterization of colorectal neoplasia with different published classifications: comparative study involving CONECCT classificationEndosc Int Open 2022; 10(01): E145-E153DOI: 10.1055/a-1613-5328 Comment on: Endoscopic management of cystic duct stones and Mirizzi’s syndrome: experience at an academic medical centerEndosc Int Open 2022; 10(01): E135-E144DOI: 10.1055/a-1594-1515 Comment on: Endoscopic submucosal dissection for colorectal neoplasia: outcomes and predictors of recurrenceEndosc Int Open 2022; 10(01): E127-E134DOI: 10.1055/a-1551-3058
Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial
Authors: John R Geddes, Alexandra Gardiner, Jennifer Rendell, Merryn Voysey, Elizabeth Tunbridge, Christopher Hinds, Ly-Mee Yu, Jane Hainsworth, Mary-Jane Attenburrow, Judit Simon, Guy M Goodwin, Paul J Harrison
Journal: The Lancet Psychiatry (2015)

BackgroundDepressive symptoms are a major cause of disability in bipolar disorder and there are few safe and effective treatments. The combination of lamotrigine plus quetiapine potentially offers improved outcomes for people with bipolar depression. We aimed to determine if combination therapy with quetiapine plus lamotrigine leads to greater improvement in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.MethodsIn this double-blind, randomised, placebo-controlled, parallel group, 2 × 2 factorial trial (CEQUEL), patients with DSM-IV bipolar disorder I or II, who were aged 16 years or older, and required new treatment for a depressive episode, were enrolled from 27 sites in the UK. Patients were randomly assigned (1:1) by an adaptive minimisation algorithm to lamotrigine or placebo and to folic acid or placebo. Participants and investigators were masked to the treatment groups. The primary outcome was improvement in depressive symptoms at 12 weeks with the Quick Inventory of Depressive Symptomatology—self report version 16 (QIDS-SR16). Analysis was by modified intention-to-treat. This trial is registered with EUdraCT, number 2007-004513-33.FindingsBetween Oct 21, 2008, and April 27, 2012, 202 participants were randomly assigned; 101 to lamotrigine and 101 to placebo. The mean difference in QIDS-SR16 total score between the group receiving lamotrigine versus the placebo group at 12 weeks was −1·73 ([95% CI −3·57 to 0·11]; p=0·066) and at 52 weeks was −2·69 ([–4·89 to −0·49]; p=0·017). Folic acid was not superior to placebo. There was a significant interaction (p=0·028), with folic acid reducing the effectiveness of lamotrigine at 12 weeks. The mean difference on QIDS-SR16 was −4·14 ([95% CI −6·90 to −1·37]; p=0·004) for patients receiving lamotrigine without folic acid compared with 0·12 ([–2·58 to 2·82]; p=0·931) for those receiving lamotrigine and folic acid.InterpretationAddition of lamotrigine to quetiapine treatment improved outcomes. Folic acid seems to nullify the effect of lamotrigine. CEQUEL should encourage clinicians and patients to consider lamotrigine for bipolar depression, but also to be aware that concurrent folic acid might reduce its effectiveness.FundingMedical Research Council.
Endoscopy, videosession
Authors: A Langnas, D Antonson, J Vanderhoof, D Mack, I Fox, T Heffron, E Quigley, B Shaw
Journal: Gut (1994)

3rd UEGW Oslo 1994 A3 4 reported frequent hiccup. 51patients maintained the ability to belch.Excellent or good results (Visick grade 1 and 2) were obtained in 55 patients (88.7%).The main reason for unsatisfaction was abdominal meteorism.Ra- diological evaluation demonstrated normal continent valve, without stenosis in 50 patients (80%). 6patients had an intrathoraci wrap without symptoms. 6patients had a partially or completely disrupted valve. 1 patient had a slipped Nissen.The radiological findings corresponded to the described symptoms in 60 patients (95%).Twenty four hours pH monitoring is the more sensitive and sensible to detect gastroesophageal reflux.However, upper GI barium series is certainly more easely accepted by the patients and may help in selecting the patients who will need further evaluation.These results of the early experience with laparoscopic antireflux surgery are encouraging.
Surveillance for Violent Deaths — National Violent Death Reporting System, 39 States, the District of Columbia, and Puerto Rico, 2018
Authors: Kameron J. Sheats, Rebecca F. Wilson, Bridget H. Lyons, Shane P.D. Jack, Carter J. Betz, Katherine A. Fowler
Journal: MMWR Surveillance Summaries (2022)

In 2018, approximately 68,000 persons died of violence-related injuries in the United States. This report summarizes data from CDC's National Violent Death Reporting System (NVDRS) on violent deaths that occurred in 39 states the District of Columbia, and Puerto Rico in 2018. Results are reported by sex, age group, race and ethnicity, method of injury, type of location where the injury occurred, circumstances of injury, and other selected characteristics.
Vaccine efficacy and iron deficiency: an intertwined pair?
Authors: Hal Drakesmith, Sant-Rayn Pasricha, Ioav Cabantchik, Chaim Hershko, Guenter Weiss, Domenico Girelli, Nicole Stoffel, Martina U Muckenthaler, Elizabeta Nemeth, Clara Camaschella, Paul Klenerman, Michael B Zimmermann
Journal: The Lancet Haematology (2021)
A Phase 1, Randomized Study Evaluating the Safety Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single Ascending Doses of Epinephrine Prodrug 109 Sublingual Film (AQST-109) in Healthy Male Volunteers
Authors: John Oppenheimer, Steve Wargacki, Rajesh Kainthan, Shawn Berg, Cathie Leister, Mark Lepore
Journal: Journal of Allergy and Clinical Immunology (2022)
Comments on: “Endoscopic prediction of submucosal invasion in Barrett’s cancer with the use of artificial intelligence: a pilot study”
Authors: Zetao Liu, Linjie Guo
Journal: Endoscopy (2022)

See also: Endoscopic prediction of submucosal invasion in Barrett's cancer with the use of artificial intelligence: a pilot studyEndoscopy 2021; 53(09): 878-883DOI: 10.1055/a-1311-8570
IFNG is constitutively expressed by esophagus-resident CD8+ T cells and is poised to mediate a disease-specific effect via its action on IFNGR+ eosinophils during active EoE
Authors: Caitlin Burk, Duncan Morgan, Bert Ruiter, Qian Yuan, J. Christopher Love, Wayne Shreffler
Journal: Journal of Allergy and Clinical Immunology (2022)
Reversal of Raynaud's phenomenon
Authors: E. F. Schmerl
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Authors: Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Récher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Tiu, Mark J. Levis
Journal: Blood (2022)

Abstract The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib in these patients with AML. At the time of this analysis, the median survival follow-up was 37.1 months, with deaths in 203 of 247 and 97 of 124 patients in the gilteritinib and SC arms, respectively; 16 gilteritinib-treated patients remained on treatment. The median overall survival for the gilteritinib and SC arms was 9.3 and 5.6 months, respectively (hazard ratio, 0.665; 95% confidence interval [CI], 0.518, 0.853; two-sided P = .0013); 2-year estimated survival rates were 20.6% (95% CI, 15.8, 26.0) and 14.2% (95% CI, 8.3, 21.6). The gilteritinib-arm 2-year cumulative incidence of relapse after composite complete remission was 75.7%, with few relapses occurring after 18 months. Overall, 49 of 247 patients in the gilteritinib arm and 14 of 124 patients in the SC arm were alive for ≥2 years. Twenty-six gilteritinib-treated patients remained alive for ≥2 years without relapse; 18 of these patients underwent transplantation (hematopoietic stem cell transplantation [HSCT]) and 16 restarted gilteritinib as post-HSCT maintenance therapy. The most common adverse events of interest during years 1 and 2 of gilteritinib therapy were increased liver transaminase levels; adverse event incidence decreased in year 2. Thus, continued and post-HSCT gilteritinib maintenance treatment sustained remission with a stable safety profile. These findings confirm that prolonged gilteritinib therapy is safe and is associated with superior survival vs SC. This trial was registered at www.clinicaltrials.gov as #NCT02421939.
Donor and Host Coexpressing KIR Ligands Promote NK Education Post Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xingxing Yu, Xiang-Yu Zhao, Zhengli Xu, Xunhong Cao, Mingrui Huo, Xiao-Su Zhao, Ying-Jun Chang, Yu Wang, Xiaohui Zhang, Lanping Xu, Kaiyan Liu, Xiaojun Huang
Journal: Blood (2019)
A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination
Authors: Sarah F. Andrews, Julie E. Raab, Jason Gorman, Rebecca A. Gillespie, Crystal S. F. Cheung, Reda Rawi, Lauren Y. Cominsky, Jeffrey C. Boyington, Adrian Creanga, Chen-Hsiang Shen, Darcy R. Harris, Adam S. Olia, Alexandra F. Nazzari, Tongqing Zhou, Katherine V. Houser, Grace L. Chen, John R. Mascola, Barney S. Graham, Masaru Kanekiyo, Julie E. Ledgerwood, Peter D. Kwong, Adrian B. McDermott
Journal: Nature Medicine (2022)
SOME FACTORS IN GASTRIC SECRETION
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Remarks on the 'Muscular Sense', and on the Physiology of Thinking
Authors: H. C. Bastian
Journal: BMJ (1869)

ONE of the cases carefully recorded by Dr. Bazire possesses the greatest interest with reference to the "muscular sense".It is related in detail by him (Trousseau's Lectures, transl.by Bazire, Pt.I, Case VI, p. I93), but I will quote only the part which more immediately refers to this subject.The patient was a cabman, thirty-twvo years of age; and Dr. Bazire's notes run thus.
Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
Authors: Marcus Maurer, Thomas Casale, Sarbjit Saini, Moshe Ben-Shoshan, Nikhil Amin, Allen Radin, Bolanle Akinlade, Chunpeng Fan, Deborah Bauer, Elizabeth Laws, Leda Mannent, Aleksandra Stjepanovic
Journal: Journal of Allergy and Clinical Immunology (2022)
Covid-19 as a long multiwave event: implications for responses to safeguard younger generations
Authors: Mandeep Dhaliwal, Roy Small, Douglas Webb, Lucie Cluver, Mona Ibrahim, Ludo Bok, Collin Nascimento, Cheng Wang, Aidan Garagic, Lars Jensen
Journal: BMJ (2022)

The World We WanT Covid-19 as a long multiwave event: implications for responses to safeguard younger generations Mandeep Dhaliwal and colleagues call for urgent correction of the response to covid-19 to safeguard the development of children and young people • Evidence from other epidemics sug- gest investment in social protection, evidence based parenting support, education re-enrolment, and child health promotion can mitigate the effects of covid-19 on 16 July
Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania
Authors: Günther Fink, Sigilbert Mrema, Salim Abdulla, S. Patrick Kachur, Rashid Khatib, Christian Lengeler, Honorati Masanja, Fredros Okumu, Joanna Schellenberg
Journal: New England Journal of Medicine (2022)

It has been hypothesized that in high-transmission settings, malaria control in early childhood (<5 years of age) might delay the acquisition of functional immunity and shift child deaths from younger to older ages.
The Freudian influence
Authors: C. D. Aring
Journal: JAMA (1977)

THE IDEAS of Sigmund Freud have had the widest impact in medicine and have also influenced anthropology, education, sociology, art, literature, and other areas. His ideas have filtered into the common consciousness. I recall words uttered long ago by my revered chief, Stanley Cobb, to the effect that one needn't concern himself about the seeming resistance to Freudian principles, since they are engrained in the culture and ubiquitous. Freud is honored even in resistance to his precepts. Like anyone leading a new cause, Freud attracted a number of followers, naturally nowhere near as wise or innovative as their master. They attempted to fix the discipline into pattern and hold it steady, seemingly unaware of or indifferent to Freud's observation that "it is the external changefulness of life that makes it so beautiful." By word and deed Freud advocated change; one need only examine his career to see how he continued